NeuroPace Inc. Reports Q4 Results and Forecasts for 2026
NeuroPace Inc., a commercial‑stage medical‑device company specializing in implantable responsive stimulation devices for neurological disorders, released its fourth‑quarter earnings on March 3, 2026. The company presented its financial results during a quarterly conference call scheduled for March 3, 2026, and outlined expectations for the remainder of the fiscal year.
Q4 2025 Financial Highlights
| Metric | Estimate | Actual/Guidance |
|---|---|---|
| Net loss per share | –$0.156 | (reported) |
| Revenue | $24.8 million | (reported) |
| Revenue growth vs. Q4 2024 | +15.3 % | (reported) |
NeuroPace’s analysts project a 15.3 % increase in quarterly revenue compared with the same period in the previous year, driven by the growth of its responsive neurostimulation product line. The company’s net loss per share is expected to be less negative than in the prior quarter, moving from a forecasted –$0.180 to –$0.156.
Fiscal‑Year 2025 Outlook
| Metric | Estimate |
|---|---|
| Net loss per share | –$0.765 |
| Revenue | $95.1 million |
The company forecasts a net loss of $0.765 per share for the full fiscal year, an improvement over the projected $0.930 loss in fiscal 2024. Revenue is expected to reach $95.1 million, up from $79.9 million in the previous year.
Market Context
DelveInsight’s recent market analysis (published March 2, 2026) projects that the global implanted brain‑computer interface devices market will expand at a compound annual growth rate of approximately 10 % through 2032. The report cites rising incidences of neurological and movement disorders, as well as increased adoption of digital health technologies, as primary growth drivers. North America is identified as the largest market region, with hardware devices representing the dominant product segment.
NeuroPace is highlighted as one of the key players in this segment, alongside Blackrock Neurotech, Synchron, LivaNova, and BrainGate. The company’s focus on responsive stimulation and its established product portfolio position it to capture a share of the anticipated market expansion.
Stock Performance
As of February 23, 2026, NeuroPace’s closing price was $14.56. The company’s market capitalization stands at approximately $485 million. The 52‑week trading range has been $7.56 to $18.98, reflecting significant volatility amid evolving market conditions and earnings expectations.
Conclusion
NeuroPace’s Q4 results indicate incremental improvement in revenue growth and a narrowing of losses, while the company’s outlook for the full fiscal year reflects optimism about its product pipeline and the expanding market for implanted neural devices. Analysts will monitor the company’s progress against the backdrop of a rapidly growing industry projected to rise at roughly 10 % CAGR through 2032.
